513 related articles for article (PubMed ID: 11299809)
1. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.
De Marinis L; Mancini A; Izzi D; Bianchi A; Giampietro A; Fusco A; Liberale I; Rossi S; Valle D
Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871
[TBL] [Abstract][Full Text] [Related]
3. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
4. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
5. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
6. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
7. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
9. Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer.
Corsello SM; Rota CA; Putignano P; Della Casa S; Barnabei A; Migneco MG; Vangeli V; Barini A; Mandalà M; Barone C; Barbarino A
Eur J Endocrinol; 1998 Sep; 139(3):309-13. PubMed ID: 9758441
[TBL] [Abstract][Full Text] [Related]
10. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
12. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Pritchard KI
Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
[No Abstract] [Full Text] [Related]
13. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
Guzzaloni G; Grugni G; Morabito F
Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
[TBL] [Abstract][Full Text] [Related]
14. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
16. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients.
Lønning PE; Hall K; Aakvaag A; Lien EA
Cancer Res; 1992 Sep; 52(17):4719-23. PubMed ID: 1380889
[TBL] [Abstract][Full Text] [Related]
17. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
18. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen.
Howe SR; Pass HI; Ethier SP; Matthews WJ; Walker C
Cancer Res; 1996 Sep; 56(17):4049-55. PubMed ID: 8752178
[TBL] [Abstract][Full Text] [Related]
19. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
